Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saracatinib - AstraZeneca

Next Previous
X
Search
Drug Profile

Saracatinib - AstraZeneca

Alternative Names: AZD 0530; Saracatinib difumarate

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Baylor College of Medicine; Brigham and Women's Hospital; Icahn School of Medicine at Mount Sinai; Innovative Medicines Initiative; Loyola University Chicago; National Center for Advancing Translational Sciences; National Jewish Health; NHS National Services Scotland; Royal National Orthopaedic Hospital; Sheffield Teaching Hospitals NHS Foundation Trust; Stanford University; University of Cincinnati; University of Miami; University of Oxford; University of South Florida; VU University Medical Center; Yale University
  • Class Analgesics; Antidementias; Antineoplastics; Benzodioxoles; Quinazolines; Small molecules
  • Mechanism of Action Src-family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Cancer pain; Fibrodysplasia ossificans progressiva; Lymphangioleiomyomatosis
  • Phase I/II Idiopathic pulmonary fibrosis
  • Preclinical Non-small cell lung cancer
  • No development reported Alcoholism; Parkinson's disease
  • Discontinued Bone cancer; Breast cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in United Kingdom (PO, Tablet)
  • 28 May 2022 No recent reports of development identified for phase-0 development in Parkinson's-disease in United Kingdom (PO, Tablet)
  • 08 Apr 2022 Preclinical trials in Non-small cell lung cancer in United Kingdom

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top